Mode
Text Size
Log in / Sign up

Susceptibility-guided sequential therapy shows no superiority over empirical therapy for H. pylori eradicationSusceptibility-guided therapy did not beat standard treatment for stomach bug infections

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that susceptibility-guided sequential therapy did not show superiority over empirical therapy for H. pylori eradication in this trial.

This single-centre randomised controlled trial enrolled 500 treatment-naive adults with Helicobacter pylori infection in a high-resistance setting. The intervention was susceptibility-guided sequential therapy (SGT), and the comparator was empirical clarithromycin-containing quadruple therapy (ET). The primary outcome was first-line eradication.

For the intention-to-treat population, eradication was 59.8% in the SGT group versus 62.8% in the ET group, with an absolute risk difference of -3.0% and an odds ratio (OR) of 0.882 (95% CI 0.614-1.268, p = 0.499). In the per-protocol analysis, eradication was 84.4% in the SGT group versus 89.7% in the ET group, with an absolute risk difference of -5.3% and an OR of 0.620 (95% CI 0.328-1.173, p = 0.139). Both analyses showed no superiority for SGT.

Safety and tolerability data were not reported. Key limitations include the single-centre design and that the benefits of susceptibility-guided therapy in high-resistance settings remain incompletely understood. The practice relevance is implications for treatment strategy selection in high-resistance microbiological settings. The empirical therapy maintained satisfactory efficacy.

Doctors often worry that stomach bugs are becoming resistant to common medicines. In places where this problem is severe, they sometimes test for specific resistance before starting treatment. This approach is called susceptibility-guided therapy. The goal is to pick the right drug immediately instead of guessing. A new study looked at whether this careful testing actually helps patients get better faster.

Researchers treated 500 adults who had never received antibiotics for this specific bug before. Half of them got treatment based on the test results. The other half received the standard first-choice medicine used in that high-resistance area. The main goal was to see if the tested group had higher cure rates.

The results showed no clear winner. About 60 percent of people in the standard treatment group were cured. The group that used the test results saw similar success rates. The difference was small and not statistically significant. This means the extra testing did not provide a better outcome for these patients.

Safety issues were not reported in this study. However, the researchers noted that this trial took place in only one medical center. They also admitted that the full benefits of this testing strategy in tough environments remain unclear. Standard treatment still holds its ground as a reliable option.

What this means for you:
Testing for resistance did not improve cure rates over standard treatment in this study.

Study Details

Study typeRct
EvidenceLevel 2
PublishedJun 2026
View Original Abstract ↓
Clarithromycin resistance is a major determinant of treatment failure, and the benefits of susceptibility-guided therapy in high-resistance settings remains incompletely understood. To evaluate the clinical effectiveness of the susceptibility-guided compared with the empirical therapy in treatment-naïve H. pylori infection in a high resistance setting. In this single-centre, randomised, superiority trial, 500 treatment-naïve adults were allocated (1:1) to susceptibility-guided sequential therapy (SGT) or empirical clarithromycin -containing quadruple therapy (ET). Clarithromycin and levofloxacin antimicrobial resistance were determined using PCR. The primary endpoint was first-line eradication in the intention-to-treat (ITT) population. Sensitivity analyses were performed using complete-case and multiple imputation approaches. Among the 494 analysed participants (244 SGT, 250 ET), resistance to clarithromycin and levofloxacin was 69.3% and 51.6%, respectively. In the ITT analysis, first-line eradication was achieved in 59.8% of participants in the SGT group and 62.8% in the ET group [absolute risk difference -3.0%; odds ratio (OR) = 0.882, 95% confidence interval (CI, 0.614-1.268), p = 0.499]. Per-protocol eradication rates were 84.4% and 89.7%, respectively [absolute risk difference -5.3%; OR = 0.620, 95% CI (0.328-1.173), p = 0.139]. Notably, despite a clarithromycin resistance rate approaching 70%, empirical clarithromycin-containing quadruple therapy achieved a high per-protocol eradication rate. Sensitivity analyses yielded consistent results. In a high resistance region, PCR-based susceptibility-guided sequential therapy did not demonstrate superiority over empirical treatment. However, empirical clarithromycin -containing quadruple therapy maintained satisfactory efficacy. Overall, these findings have implications for treatment strategy selection in high-resistance microbiological settings. Trial Registration: ClinicalTrials. gov Identifier: NCT05549115.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.